Patents Assigned to Auspex Pharmaceutical, Inc
  • Patent number: 12077487
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: September 3, 2024
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Patent number: 12016858
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 25, 2024
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: David Stamler, Michael Huang
  • Patent number: 11813232
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: November 14, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Chengzhi Zhang, James Kerr
  • Patent number: 11666566
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 6, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Patent number: 11648244
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 16, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: David Stamler, Michael Fangching Huang
  • Patent number: 11564917
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: January 31, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: David Stamler, Michael Fangching Huang
  • Patent number: 11446291
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 20, 2022
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: David Stamler, Michael Fangching Huang
  • Patent number: 11357772
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: June 14, 2022
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: David Stamler, Michael Huang
  • Patent number: 11324732
    Abstract: The disclosure is directed to methods of treating dyskinesia in cerebral palsy in human patients using deutetrabenazine and its active metabolites.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 10, 2022
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Juha-Matti Savola, Mark Forrest Gordon, Frank Schneider
  • Patent number: 11311488
    Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: April 26, 2022
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
  • Patent number: 11179386
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: November 23, 2021
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Chengzhi Zhang, James Kerr
  • Patent number: 11033540
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 15, 2021
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Patent number: 10966922
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 6, 2021
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • Patent number: 10959996
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: March 30, 2021
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: David Stamler, Michael Fangching Huang
  • Patent number: 10722479
    Abstract: Described are dimethoxyphenyl inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: July 28, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Patent number: 10689370
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 23, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Chengzhi Zhang, Justin Chakma
  • Patent number: 10626105
    Abstract: Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 21, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Patent number: 10568965
    Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: February 25, 2020
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Patent number: 10513488
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 24, 2019
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Patent number: 10421710
    Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: September 24, 2019
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Thomas G. Gant, Sepehr Sarshar, Soon Hyung Woo